| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Gamunex - C vs Vyvgart Hytrulo
Side-by-side clinical, coverage, and cost comparison for polyradiculoneuropathy, chronic inflammatory demyelinating.Deep comparison between: Gamunex-C vs Vyvgart Hytrulo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyvgart Hytrulo has a higher rate of injection site reactions vs Gamunex-C based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyvgart Hytrulo but not Gamunex-C, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gamunex-C
Vyvgart Hytrulo
At A Glance
IV infusion / SC injection
Every 3-4 weeks
Immune globulin
SC injection
Once weekly
FcRn blocker
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Congenital agammaglobulinemia
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Myasthenia Gravis, Generalized
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency, Congenital agammaglobulinemia IV: 300-600 mg/kg every 3-4 weeks; SC: initial weekly dose = prior monthly IGIV dose (g) x 1.37 divided by the number of weeks between IV doses, adjusted based on clinical response and IgG trough levels.
Immune thrombocytopenic purpura IV only: total dose of 2 g/kg given as 1 g/kg on two consecutive days or 0.4 g/kg on five consecutive days; do not administer subcutaneously.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating IV loading dose: 2 g/kg over 2-4 consecutive days; maintenance: 1 g/kg every 3 weeks (or 0.5 g/kg on two consecutive days every 3 weeks).
Myasthenia Gravis, Generalized 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly for 4-week cycles (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); subsequent cycles based on clinical evaluation.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); continue based on clinical response.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity reaction
- Serious hypersensitivity to efgartigimod alfa products, hyaluronidase, or any excipient of VYVGART HYTRULO (including anaphylaxis and hypotension leading to syncope)
Adverse Reactions
Most common (>=5%) Headache, pyrexia, nausea, cough, rhinitis, pharyngitis, asthma, diarrhea, sinusitis, vomiting, ecchymosis, rash, arthralgia, chills, hypertension, asthenia, fatigue, local infusion site reactions (SC administration), upper respiratory tract infection, back pain, dyspepsia, abdominal pain.
Serious Exacerbation of autoimmune pure red cell aplasia, pulmonary embolism, hemolytic anemia.
Postmarketing Anaphylaxis, tachycardia, acute renal dysfunction/failure, acute respiratory distress syndrome, TRALI, pulmonary edema, bronchospasm, cardiac arrest, thromboembolism, vascular collapse, coma, seizures, aseptic meningitis, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, pancytopenia, leukopenia, hemolytic anemia, hepatic dysfunction.
Most common (>=10%) Injection site reactions (rash, erythema, pruritus, bruising, pain, urticaria), headache
Serious Infections, hypersensitivity reactions (including anaphylaxis and hypotension), infusion/injection-related reactions
Postmarketing Hypersensitivity reactions including anaphylaxis and hypotension, infusion/injection-related reactions, worsening of CIDP symptoms when transitioning from intravenous immunoglobulin treatment
Pharmacology
GAMUNEX-C supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins; the precise mechanisms of action in ITP and CIDP have not been fully elucidated.
Efgartigimod alfa, a human IgG1 Fc fragment, binds to the neonatal Fc receptor (FcRn) and reduces circulating IgG; co-formulated hyaluronidase transiently depolymerizes hyaluronan to increase subcutaneous tissue permeability for 24 to 48 hours.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gamunex-C
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (7/12) · Qty limit (0/12)
Vyvgart Hytrulo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Gamunex-C
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Vyvgart Hytrulo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Gamunex-C
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Vyvgart Hytrulo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gamunex-C.
No savings programs available for Vyvgart Hytrulo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Gamunex-CView full Gamunex-C profile
Vyvgart HytruloView full Vyvgart Hytrulo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.